Topoisomerase inhibitors are a vital class of chemotherapy drugs used in specific lung cancer treatments. They work by blocking enzymes essential for DNA replication, which disrupts cell division and triggers cancer cell death. The increasing focus on DNA-topoisomerases highlights their importance in DNA processes and their potential as targets for new anticancer therapies. By inhibiting these enzymes, particularly after DNA damage and repair failures, these drugs effectively kill rapidly dividing tumor cells, making them a promising avenue in cancer treatment.
